TABLE 2.
Mouse straina | Source of virus | Age | Dose | Infectionb by: |
Death | Limb paralysis | Skin rash | Spleen fibrosis | VP1 detection by IHC | Hematological abnormalities | Leukocyte infiltration | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Nonoral routec | Oral route | |||||||||||
ICR | Serial passage adaptive | 1 day–1 wk | 2 × 105–5 × 106 PFU | + | + | + | + | − | − | Brain, spinal cord | ND | ND |
ip-10 KO | Serial passage adaptive | 2 wk | 3 × 105 PFU | + | ND | + | + | − | − | Brain | ND | ND |
AG129 | Clinical isolate | 2 wk | 5 × 105–107 PFU | + | + | + | + | − | − | Brain stem | ND | ND |
pEF-1α-hSCARB2 Tg | Clinical isolate | 1 wk | 3 × 104–107 PFU | + | ND | + | + | −d | − | Brain stem, spinal cord, intestine, muscle, skin | ND | ND |
pSC2-hSCARB2 Tg | Clinical isolate | 3–6 wk | 102–106 TCID50 | + | 2/50e | +f | +f | − | − | Pons, medulla, cerebellar nuclei, spinal cord | ND | CD3+ T cells in brain, spinal cord, intestine, lung, muscle, skin |
NOD/SCID | Clinical isolate | 1 wk | 107 PFU | + | + | + | + | + | + | Spleen, muscle, skin | +g | Macrophages in muscle |
stat-1 KO | Clinical isolate | 1 wk | 108 PFU | + | ND | − | + | − | + | Pons, Purkinje layer, superior colliculus, spinal cord | ND | ND |
See reference 8 for ICR mice, reference 27 for ip-10 KO mice, reference 12 for AG129 mice, reference 17 for pEF-1α-hSCARB2-Tg mice, and reference 16 for pSC2-hSCARB2-Tg mice.
ND, not done.
Including the intraperitoneal, intracerebral, intravenous, and subcutaneous routes.
Hair loss associated with scurf, but no skin rash.
Number of mice infected/total number of mice in a total of three experiments in which 1/20, 1/20, and 1/10 mice were infected, respectively.
Ataxia, paralysis, and death are defined as the same event in reference 16.
See Fig. 4. The number of neutrophils and the red blood cell distribution width were increased, and the numbers of lymphocytes and eosinophils, mean cell volume, and mean cell hemoglobin were decreased, in EV71-infected mice.